Patients who have intrahepatic cholangiocarcinoma caused by specific FGFR2 gene alterations may soon have a better treatment option that more successfully targets that mutation.
FDA announced the final withdrawal of the approval of infigratinib (Truseltiq) for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement.
